文献速递创伤与烧伤心脑血管急症

抗CD49d抗体治疗改善老年小鼠创伤性脑损伤后的生存并减轻神经认知缺陷

ANTI-CD49D ANTIBODY TREATMENT IMPROVES SURVIVAL AND ATTENUATES NEUROCOGNITIVE DEFICITS AFTER TRAUMATIC BRAIN INJURY IN AGED MICE.
PubMed 文献 · Shock · 2023-11-15
一句话结论在老年雄性C57BL/6小鼠中,伤后2小时给予抗CD49d抗体并每2周重复,可改善TBI后2个月的生存、焦虑、联想学习、记忆和运动功能,而在年轻小鼠中未检测到差异。

老年(65岁及以上)TBI患者发病率和死亡率高于年轻患者,既往研究发现老年TBI小鼠脑内CD8+ T细胞显著积聚。本研究让年轻和老年雄性C57BL/6小鼠接受控制性皮层撞击或假损伤,伤后2小时给予抗CD49d抗体(阻断外周淋巴细胞浸润)或同型对照,每2周重复给药,追踪死亡率并进行神经认知和运动功能测试。结果:老年小鼠中抗CD49d抗体组TBI后2个月的生存、焦虑水平、联想学习、记忆和运动功能均显著改善,血浆TH2反应增强,脑内活化CD8+细胞毒性T细胞显著减少;年轻小鼠中未检测到差异。作者认为抗CD49d抗体可能是有前景的老年TBI治疗干预。

要点

  • 老年雄性C57BL/6小鼠TBI后2小时给予抗CD49d抗体并每2周重复,TBI后2个月生存、焦虑、联想学习、记忆和运动功能较同型对照显著改善。
  • 抗CD49d抗体治疗显著减少老年小鼠TBI后脑内活化CD8+细胞毒性T细胞,并增强血浆TH2反应。
  • 年轻小鼠接受抗CD49d抗体治疗后未检测到差异。
  • 作者认为抗CD49d抗体可能是老年TBI受试者(常被TBI临床试验排除的人群)有前景的治疗干预。

适用人群与场景

  • 年轻和老年雄性C57BL/6小鼠,接受控制性皮层撞击或假损伤。
  • 对应人群:65岁及以上TBI患者——该人群发病率和死亡率高于年轻TBI患者,且常被TBI临床试验排除。

处置流程与药物剂量

  • 伤后2小时给予抗CD49d抗体以阻断外周淋巴细胞浸润,或给予同型对照;给药每2周重复一次。

研究设计与关键结果

  • 研究类型:动物实验;年轻和老年雄性C57BL/6小鼠接受控制性皮层撞击或假损伤。
  • 干预与对照:伤后2小时给予抗CD49d抗体或同型对照,每2周重复给药。
  • 主要终点:老年小鼠TBI后2个月,抗CD49d抗体组较同型对照组的生存、焦虑水平、联想学习、记忆和运动功能显著改善。
  • 机制终点:老年小鼠TBI后2个月,抗CD49d抗体组血浆TH2反应较同型对照组增强,脑内活化CD8+细胞毒性T细胞显著减少。
  • 亚组:年轻小鼠接受抗CD49d抗体治疗后未检测到差异。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠TBI模型)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为抗CD49d抗体可能是老年TBI受试者(常被TBI临床试验排除的人群)有前景的治疗干预。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Patients 65 years and older account for an increasing proportion of traumatic brain injury (TBI) patients. Aged TBI patients experience increased morbidity and mortality compared with young TBI patients. We previously demonstrated a marked accumulation of CD8 + T-cells within the brains of aged TBI mice compared with young TBI mice. Therefore, we hypothesized that blocking peripheral T-cell infiltration into the injured brain would improve neurocognitive outcomes in aged mice after TBI. Young and aged male C57BL/6 mice underwent TBI via controlled cortical impact versus sham injury. Two hours after injuries, mice received an anti-CD49d antibody (aCD49d Ab) to block peripheral lymphocyte infiltration or its isotype control. Dosing was repeated every 2 weeks. Mortality was tracked. Neurocognitive testing for anxiety, associative learning, and memory was assessed. Motor function was evaluated. Plasma was collected for cytokine analysis. Flow cytometry was used to phenotype different immune cells within the brains. Consequently, aCD49d Ab treatment significantly improved post-TBI survival, anxiety level, associative learning, memory, and motor function in aged mice 2 months after TBI compared with isotype control treated mice. aCD49d Ab treatment augmented T H 2 response in the plasma of aged mice 2 months after TBI compared with isotype control-treated mice. Notably, aCD49d Ab treatment significantly reduced activated CD8 + cytotoxic T-cells within aged mouse brains after TBI. Contrastingly, no difference was detected in young mice after aCD49d Ab treatment. Collectively, aCD49 Ab treatment reduced T-cells in the injured brain, improved survival, and attenuated neurocognitive and gait deficits. Hence, aCD49d Ab may be a promising therapeutic intervention in aged TBI subjects-a population often excluded in TBI clinical trials.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Chen Z, Ford K, Islam M, et al. ANTI-CD49D ANTIBODY TREATMENT IMPROVES SURVIVAL AND ATTENUATES NEUROCOGNITIVE DEFICITS AFTER TRAUMATIC BRAIN INJURY IN AGED MICE. Shock. 2023. PMID: 38010092. doi:10.1097/SHK.0000000000002256

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。